|
| 36445624 | Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y<sub>12</sub> Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study. | Cardiovasc Drugs Ther | 2024 |
| 36335918 | Survival After Invasive or Conservative Management of Stable Coronary Disease. | Circulation | 2023 |
| 37604357 | Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA Trials. | Am Heart J | 2023 |
| 37045502 | Genetic-Guided Oral P2Y<sub>12</sub> Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention. | JACC Cardiovasc Interv | 2023 |
| 37039791 | Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. | JAMA | 2023 |
| 35259918 | Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. | Circulation | 2022 |
| 35709825 | Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. | Lancet Respir Med | 2022 |
| 35504307 | Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia. | Chest | 2022 |
| 35699977 | Patient Onboarding and Engagement to Build a Digital Study After Enrollment in a Clinical Trial (TAILOR-PCI Digital Study): Intervention Study. | JMIR Form Res | 2022 |
| 35598636 | The trial to assess chelation therapy 2 (TACT2): Rationale and design. | Am Heart J | 2022 |
| 34953032 | Chasing the storm: Recruiting non-hospitalized patients for a multi-site randomized controlled trial in the United States during the COVID-19 pandemic. | Clin Transl Sci | 2022 |
| 35149037 | Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. | Am Heart J | 2022 |
| 33129990 | Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry. | Am Heart J | 2021 |
| 33744207 | Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y<sub>12</sub> Inhibitor Therapy: A Meta-Analysis. | JACC Cardiovasc Interv | 2021 |
| 34521217 | Outcomes of Participants With Diabetes in the ISCHEMIA Trials. | Circulation | 2021 |
| 34245691 | Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop. | Lancet Respir Med | 2021 |
| 32511001 | Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop. | Circulation | 2020 |
| 31992065 | Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. | Circulation | 2020 |
| 31744331 | Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. | Circulation | 2020 |
| 32821856 | Digitizing clinical trials. | NPJ Digit Med | 2020 |
| 32703515 | Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. | J Am Coll Cardiol | 2020 |
| 32586583 | Recurrence of Atrial Fibrillation After Catheter Ablation or Antiarrhythmic Drug Therapy in the CABANA Trial. | J Am Coll Cardiol | 2020 |
| 32298849 | National Heart, Lung, and Blood Institute cardiovascular clinical trial perspective. | Am Heart J | 2020 |
| 32227753 | Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. | N Engl J Med | 2020 |
| 28431138 | Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. | Eur Heart J | 2019 |
| 30810700 | Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. | JAMA Cardiol | 2019 |
| 30998396 | Clopidogrel Pharmacogenetics. | Circ Cardiovasc Interv | 2019 |
| 30874766 | Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. | JAMA | 2019 |
| 30874716 | Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. | JAMA | 2019 |
| 30415610 | Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. | N Engl J Med | 2019 |
| 29224648 | Effect of high-dose oral multivitamins and minerals in participants not treated with statins in the randomized Trial to Assess Chelation Therapy (TACT). | Am Heart J | 2018 |
| 29754661 | Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. | Am Heart J | 2018 |
| 29778671 | International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. | Am Heart J | 2018 |
| 28030716 | Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. | JAMA Cardiol | 2017 |
| 28455296 | Streamlining cardiovascular clinical trials to improve efficiency and generalisability. | Heart | 2017 |
| 28104770 | Decline in Cardiovascular Mortality: Possible Causes and Implications. | Circ Res | 2017 |
| 29191332 | Role of Payers in the Development of Cardiovascular Therapeutics: Misalignment Between Approval and Reimbursement. | J Am Coll Cardiol | 2017 |
| 28760208 | Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. | Am Heart J | 2017 |
| 27747305 | Detection and Management of Geographic Disparities in the TOPCAT Trial: Lessons Learned and Derivative Recommendations. | JACC Basic Transl Sci | 2016 |
| 26403339 | Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction. | J Am Coll Cardiol | 2015 |
| 24178969 | Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study. | Clin J Am Soc Nephrol | 2014 |
| 24987051 | Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial. | Circ Cardiovasc Qual Outcomes | 2014 |
| 24792735 | One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial). | Am J Cardiol | 2014 |
| 24952858 | EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. | Am Heart J | 2014 |
| 24254885 | The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). | Circ Cardiovasc Qual Outcomes | 2014 |
| 24016491 | Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. | Am Heart J | 2013 |
| 24490264 | Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. | Ann Intern Med | 2013 |
| 24251361 | A pharmacogenetic versus a clinical algorithm for warfarin dosing. | N Engl J Med | 2013 |
| 22424000 | Study design for the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care (IMMEDIATE) Trial: A double-blind randomized controlled trial of intravenous glucose, insulin, and potassium for acute coronary syndromes in emergency medical services. | Am Heart J | 2012 |
| 23008471 | Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. | Circulation | 2012 |